Bristol-Myers Falls as It Cites Drug-Trial Questions

Bristol-Myers Squibb Co. plunged the most in 17 months after the drugmaker said it wasn’t ready to move ahead with a study of a combination cancer treatment that includes the company’s top prospect.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.